Under Patronage


The increasing availability of biosimilar medicines in MENA regions provides an opportunity for patients to have access to traditionally more expensive biologic medicines. However, lack of understanding the development pathway for biosimilars combined with the availability of non-comparable biologics, also known as intended copies, may undermine physician confidence in prescribing legitimate biosimilar medicines. The regulators also need to ensure that…

Rabat, Morocco

21-22 June


10 Speakers

Best Experts

100 Seats

Places are limited

Program Highlights 2019

Biosimilars Registration

EU, US & MENA region

Clinical Data Requirements

Regulations & Responsibilities


Safety Assessment prior to registration

Manufacturing and Quality

Biologic manufacturing

Why Attend

Meet New Faces

AMONG THE PARTICIPANTS: Health Policy makers, Pharmaceutical companies, CRO Hospitals management, Physicians, international experts

Get Inspired

A TWO-DAY PROGRAMME, filled with analyses and new top experts

Informative Platform

INTERACTIVE FORMATS, including discussions, Q&A, debates and interview

More Detail